Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma – SEATTLE-
Condition(s):Multiple MyelomaLast Updated:July 20, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:July 20, 2023Recruiting
Condition(s):Non-Small Cell Lung Cancer (NSCLC)Last Updated:January 24, 2024Recruiting
Condition(s):Lymphedema; Lymphatic Filariasis; FilariasisLast Updated:March 17, 2021Completed
Condition(s):Lymphedema; Lymphatic Filariasis; FilariasisLast Updated:June 24, 2021Completed
Condition(s):Chronic Disease; Cardiovascular Diseases; Hypertension; Diabetes; Pre-diabetes; ObesityLast Updated:May 9, 2022Completed
Condition(s):Stroke; Cerebral Infarction; Cerebral Hemorrhage; Stroke Hemorrhagic; Stroke, Ischemic; Stroke of Uncertain PathologyLast Updated:July 26, 2018Completed
Condition(s):Diabetes Mellitus, Type 2; Hypertension; DyslipidemiasLast Updated:March 12, 2021Completed
Condition(s):Neisseria Gonorrhoeae InfectionLast Updated:July 15, 2021Completed
Condition(s):HER2-positive Breast CancerLast Updated:March 31, 2023Recruiting
Condition(s):HIVLast Updated:August 28, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.